GSA Capital Partners LLP Makes New Investment in Nuvation Bio Inc. (NYSE:NUVB)

GSA Capital Partners LLP purchased a new stake in shares of Nuvation Bio Inc. (NYSE:NUVB) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 74,932 shares of the company’s stock, valued at approximately $172,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Nuvation Bio by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 7,534,148 shares of the company’s stock valued at $27,424,000 after purchasing an additional 219,533 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Nuvation Bio by 551.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,354,632 shares of the company’s stock worth $4,932,000 after buying an additional 1,146,794 shares during the period. Dimensional Fund Advisors LP grew its holdings in Nuvation Bio by 415.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,018,329 shares of the company’s stock worth $2,975,000 after buying an additional 820,669 shares in the last quarter. Panagora Asset Management Inc. increased its position in Nuvation Bio by 198.7% in the 2nd quarter. Panagora Asset Management Inc. now owns 633,676 shares of the company’s stock valued at $1,850,000 after acquiring an additional 421,563 shares during the period. Finally, Algert Global LLC raised its stake in Nuvation Bio by 281.0% during the 2nd quarter. Algert Global LLC now owns 426,603 shares of the company’s stock valued at $1,246,000 after acquiring an additional 314,635 shares in the last quarter. Institutional investors and hedge funds own 61.67% of the company’s stock.

Nuvation Bio Stock Up 3.7 %

NUVB stock opened at $2.80 on Monday. The company has a 50 day moving average of $2.51 and a two-hundred day moving average of $2.89. The company has a market cap of $942.39 million, a price-to-earnings ratio of -1.29 and a beta of 1.35. Nuvation Bio Inc. has a 12-month low of $1.22 and a 12-month high of $4.16.

Nuvation Bio (NYSE:NUVB) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $0.73 million during the quarter. On average, research analysts anticipate that Nuvation Bio Inc. will post -0.4 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Royal Bank of Canada increased their price target on Nuvation Bio from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Wedbush reissued an “outperform” rating and set a $5.00 target price on shares of Nuvation Bio in a research note on Thursday, November 7th. Finally, HC Wainwright reduced their price target on shares of Nuvation Bio from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Nuvation Bio presently has a consensus rating of “Buy” and a consensus price target of $6.60.

Insider Activity

In other Nuvation Bio news, Director Robert Mashal purchased 100,000 shares of the business’s stock in a transaction dated Tuesday, October 8th. The shares were acquired at an average price of $2.20 per share, for a total transaction of $220,000.00. Following the acquisition, the director now owns 100,000 shares of the company’s stock, valued at $220,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 5.07% of the stock is owned by corporate insiders.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.